Electrical neuromodulation in the management of lower urinary tract dysfunction: evidence, experience and future prospects

Alejandro Abello, Anurag K Das, Alejandro Abello, Anurag K Das

Abstract

Lower urinary tract dysfunction (LUTD) is common and causes a spectrum of morbidity and decreased quality of life (QoL) for patients. LUTD can range from urinary retention to urge incontinence, and includes a variety of syndromes, with the most common and widely recognized being overactive bladder (OAB). The classic treatments of LUTD and OAB comprise different strategies including behavioral therapies, medications and minimally invasive or invasive surgical procedures. Generally, once patients have tried behavioral modifications and oral medical therapy, and have not experienced adequate relief of their symptoms, the next step is to consider minimally invasive therapies. In the last two decades since FDA approval, sacral nerve stimulation (SNS) has become an accepted intervention, with increasing use and evidence of effectiveness for LUTD, specifically OAB and non-obstructive urinary retention. SNS has shown both objective and subjective improvement in voiding symptoms in several randomized controlled trials (RCTs) when compared to sham or standard medical therapy. The main limitations for more extensive use include relatively high cost, implantation of a device and possibly reoperation secondary to adverse events (AE). Percutaneous tibial nerve stimulation (PTNS) is a less invasive, less direct and less expensive method for neuromodulation, which has also shown effectiveness in several randomized and non-randomized trials, including comparable improvement rates to anticholinergics in OAB management. However, the efficacy of PTNS is only maintained for a short period after the stimulation is delivered. This technique has a much lower rate of AE compared to SNS, but with the inconvenience of weekly visits for stimulation, although implantable devices are on the horizon. In this article we review the mechanism of action, indications, effectiveness and complications related to SNS and PTNS therapy for LUTD.

Keywords: implantable neurostimulators; lower urinary tract symptoms; neuromodulation; overactive bladder; percutaneous electric nerve stimulation; urge incontinence; urinary retention.

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

    1. Moore T, Schofieldt PF. Treatment of stress incontinence by maximum stimulation. Br Med J 1967; 3: 150–151.
    1. Tanagho EA, Schmidt RA, Orvis BR. Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. J Urol 1989; 142: 340–345.
    1. Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000; 56: 87–91.
    1. van Kerrebroeck PEV, Van Voskuilen AC, Heesakkers JPFA, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007; 178: 2029–2034.
    1. FDA. PMA P080025: summary of safety and efficacy data. InterStim 2011: 1–25.
    1. Mcguire EJ, Shi-chun Z, Horwinski ER, et al. Treatment of motor and sensory detrusor instability by electrical stimulation. J Urol 1983; 129: 78–79.
    1. Cooperberg MR, Stoller ML. Percutaneous neuromodulation. Urol Clin N Am 2005; 32: 71–78.
    1. Haylen BT, De Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2009; 29: 4–20.
    1. Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008; 102: 774–779.
    1. Kacker R, Lay A, Das A. Electrical and mechanical office-based neuromodulation. Urol Clin N Am 2013; 40: 581–589.
    1. Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015; 193: 1572–1580.
    1. Abrams P, Andersson K, Birder L, et al. 4th international consultation recommendations of the International Scientific Committee: the major evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. Neurourol Urodyn 2010; 29: 213–240.
    1. Burkhard FC, Lucas MG, Berghmans LC, et al. EAU guidelines on urinary incontinence in adults. Report, European Association of Urology, 2016.
    1. Gupta P, Ehlert MJ, Sirls LT, et al. Percutaneous tibial nerve stimulation and sacral neuromodulation: an update. Curr Urol Rep 2015; 16: 4–9.
    1. Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol 2010; 67: 74–84.
    1. Amend B, Matzel KE, Abrams P, et al. How does neuromodulation work. Neurourol Urodyn 2011; 30: 762–765.
    1. Kacker R, Das AK. Selection of ideal candidates for neuromodulation in refractory overactive bladder. Curr Urol Rep 2010; 11: 372–378.
    1. Williams ER, Siegel SW. Procedural techniques in sacral nerve modulation. Int Urogynecol J 2010; 21(Suppl. 2): S453–S460.
    1. Amend B, Bedke J, Khalil M, et al. Prolonged percutaneous SNM testing does not cause infection-related explanation. BJU Int 2013; 111: 485–491.
    1. Kessler TM, Burkhard FC, Madersbacher H, et al. Safety of prolonged sacral neuromodulation tined lead testing. Curr Med Res Opin 2008; 24: 343–347.
    1. Everaert K, Kerckhaert W, Caluwaerts H, et al. A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur Urol 2004; 45: 649–654.
    1. Peters KM, Carey JM, Konstandt DB. Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14: 223–228.
    1. Faris AER, Gill BC, Pizarro-Berdichevsky J, et al. Impact of age and comorbidities on use of sacral neuromodulation. J Urol 2017; 198: 161–166.
    1. Siegel S, Noblett K, Mangel J, et al. Five year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. J Urol 2018; 199: 229–236.
    1. Peeters K, Sahai A, De Ridder D, et al. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int 2014; 113: 789–794.
    1. Al-Zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol 2011; 185: 981–986.
    1. Jonas U, Fowler CJ, Chancellor MB, et al. Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol 2001; 165: 15–19.
    1. Das AK, Carlson AM, Hull M. Improvement in depression and health-related quality of life after sacral nerve stimulation therapy for treatment of voiding dysfunction. Urology 2004; 64: 62–68.
    1. Hassouna MM, Siegel SW, Nÿeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 2000; 163: 1849–1854.
    1. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999; 162: 352–357.
    1. Rai BP, Cody JD, Alhasso A, et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev 2012; 12: CD003193.
    1. Mirbagheri N, Sivakumaran Y, Nassar N, et al. Systematic review of the impact of sacral neuromodulation on clinical symptoms and gastrointestinal physiology. ANZ J Surg 2016; 86: 232–236.
    1. Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006; 175: 835–841.
    1. Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA 2016; 316: 1366–1374.
    1. Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6 months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn 2015; 34: 224–230.
    1. Scheepens WA, de Bie RA, Weil EH, et al. Unilateral versus bilateral sacral neuromodulation in patients with chronic voiding dysfunction. J Urol 2002; 168: 2046–2050.
    1. Finazzi-Agrò E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 2010; 184: 2001–2006.
    1. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010; 183: 1438–1443.
    1. Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182: 1055–1061.
    1. Levin PJ, Siddiqui NY, Wu JM, et al. Psychosocial factors related to the use of InterStim® for the treatment of refractory overactive bladder. Female Pelvic Med Reconstr Surg 2014; 20: 272–275.
    1. Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn 2016; 35: 246–251.
    1. Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol 2013; 189: 210–216.
    1. Hassouna MM, Sadri H. Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective. Can Urol Assoc J 2015; 9: 242–247.
    1. Leong RK, De Wachter SGG, Joore MA, et al. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 2011; 108: 558–564.
    1. Elkelini MS, Hassouna MM. Safety of MRI at 1.5 Tesla in patients with implanted sacral nerve neurostimulator. Eur Urol 2006; 50: 311–316.
    1. Chermansky CJ, Krlin RM, Holley TD, et al. Magnetic resonance imaging following InterStim®: an institutional experience with imaging safety and patient satisfaction. Neurourol Urodyn 2011; 30: 1486–1488.
    1. Medtronic. MRI guidelines for InterStim therapy neurostimulation systems. Minneapolis: Medtronic, 2012.
    1. Van Der Pal F, Van Balken MR, Heesakkers JPFA, et al. Implant-driven tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: 12-month follow-up. Neuromodulation 2006; 9: 163–171.
    1. Janssen DA, Farag F, Heesakkers JP. Urgent-SQ implant in treatment of overactive bladder syndrome: 9-year follow-up study. Neurourol Urodyn 2013; 32: 472–475.
    1. Van Breda HMK, Martens FMJ, Tromp J, et al. A new implanted posterior tibial nerve stimulator for the treatment of overactive bladder syndrome: 3-month results of a novel therapy at a single center. J Urol 2017; 198: 205–210.
    1. Sanford MT, Suskind AM. Neuromodulation in neurogenic bladder. Transl Androl Urol 2016; 5: 117–126.
    1. Engeler DS, Meyer D, Abt D, et al. Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol 2015; 15: 105.
    1. Laviana A, Jellison F, Kim JH. Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome. Neurosurg Clin N Am 2014; 25: 33–46.
    1. Yamanishi T, Kaga K, Fuse M, et al. Neuromodulation for the treatment of lower urinary tract symptoms. LUTS Low Urin Tract Symptoms 2015; 7: 121–132.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir